Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005

Nephrology

Volumn 13, Issue 2, 2008, Pages 171-176

  Chang, Sean H ^a,b   Russ, Graeme R ^a,b   Chadban, Steven J ^a,c,d   Campbell, Scott ^a,e,f   McDonald, Stephen P ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d University of Sydney   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ANZDATA; Australia; Immunosuppression; Kidney transplantation; Registry

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUSTRALIA; DRUG DOSE REDUCTION; DRUG USE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANT REGISTRY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES; ANTIMETABOLITES; AUSTRALIA; AZATHIOPRINE; CALCINEURIN; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PREDNISOLONE; PROTEIN KINASES; REGISTRIES; SIROLIMUS; STEROIDS; TACROLIMUS; TIME FACTORS;

EID: 38949110302     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00859.x     Document Type: Article

References (36)

1. Chadban S, McDonald S, Chang S, Excell L, Livingston B. Transplantation. In : Mcdonald S, Excell L (eds) ANZDATA, Registry Report, 2006. Adelaide : Australia and New Zealand Dialysis and Transplant Registry, 2006 107 28.
2. Chang S, Russ G, Chadban S, Campbell B, McDonald S. Trends in Kidney Transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007 (in press).
3. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 2004 4 : 378 83.
4. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am. J. Transplant. 2006 6 (5 Part 2 1111 31.
5. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005 331 : 810.
6. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004 36 (2 Suppl. 420S 25S.
7. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J Transplant 2007 7 : 1506 14.
8. Birsan T, Loinig C, Bodingbauer M et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single-center experience. Transplantation 2004 78 : 1787 91.
9. Kyllonen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplantation 2006 81 : 1010 15.
10. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001 61 : 1957 2016.
11. Stefoni S, Midtved K, Cole E et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005 79 : 577 83.
12. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002 74 : 1070 76.
13. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transplant. 2004 4 : 1776 85.
14. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant. 2006 6 : 514 22.
15. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am. J. Transplant. 2007 7 : 560 70.
16. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J. Am. Soc. Nephrol. 2005 16 : 3015 26.
17. Bakker RC, Hollander AAMJ, Mallat MJK, Bruijn JA, Paul LC, De Fijter JW. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int. 2003 64 : 1027 34.
18. Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data. Transplantation 2007 83 : 582 7.
19. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004 78 : 1653 60.
20. Abramowicz D, Manas D, Lao M et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002 74 : 1725 34.
21. Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The 'creeping creatinine' study. Transplantation 2005 79 : 466 75.
22. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am. J. Transplant. 2004 4 : 655 62.
23. Russ G, Segoloni G, Oberbauer R et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005 80 : 1204 11.
24. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am. J. Transplant. 2005 5 : 1748 56.
25. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002 74 : 1560 7.
26. Frimat L, Cassuto-Viguier E, Charpentier B et al. Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study. Am. J. Transplant. 2006 6 : 2725 34.
27. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 2001 59 : 1567 73.
28. Kasiske BL, Chakkera HA, Louise TA, Ma JZ. A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. J. Am. Soc. Nephrol. 2000 11 : 1910 17.
29. Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004 78 : 1548 56.
30. Woodle E. A randomized, double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Three year results. Am. J. Transplant. 2006 6 (Suppl. 2 177.
31. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am. J. Kidney Dis 2001 37 : 1162 9.
32. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004 77 : 252 8.
33. Schena F, Vitko S, Wali R., Pascoe M, Alberu J, del Carmen Rial M, The Sirolimus Convert Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18-month results from a randomized, open-label comparative trial (abstract). Am. J. Transplant. 2006 6 (Suppl. 2 412.
34. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol. Dial. Transplant. 2005 20 : 2517 23.
35. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004 77 : 166 76.
36. Meier-Kriesche HU, Baliga R., Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003 75 : 1291 5.